Fate Therapeutics Expands Stem Cell Modulator Pipeline With Acquisition of Verio Therapeutics

San Diego based Fate Therapeutics has acquired Verio Therapeutics, an Ontario-based company developing drugs that target endogenous stem cells and work on muscular regeneration. “We have admired Fate’s stem cell biology expertise, proprietary induced pluripotent stem cell technology platform and its unique pharmacologic approach to stem cell medicine, which is complementary to Verio’s,” said Frank Gleeson, CEO of Verio Therapeutics in a FierceBiotech release. “Joining forces with Fate not only unites the top stem cell scientists in North America but, more significantly, creates an ideal opportunity to rapidly advance our therapeutic programs into advanced preclinical and clinical testing.”

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail